咪唑并[1,2-A]吡啶-8-甲酸甲酯 | 133427-07-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 中文名称: 咪唑并[1,2-A]吡啶-8-甲酸甲酯
• 中文别名: 咪唑并[1,2-A]吡啶-8-羧酸甲酯
• 英文名称: methyl 8-imidazo<1,2-a>pyridinecarboxylate
• 英文别名: methyl imidazo[1,2-a]pyridine-8-carboxylate；imidazo[1,2-a]pyridine-8-carboxylic acid methyl ester
• CAS: 133427-07-3
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: UJLRMEAGEVCFNJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，干燥密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl imidazo[1,2-a]pyridine-8-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl imidazo[1,2-a]pyridine-8-carboxylate
CAS number: 133427-07-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8N2O2
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  咪唑并[1,2-A]吡啶-8-甲酸甲酯 在 lithium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 反应 1.5h， 生成 8-羧酸咪唑并[1,2-A]吡啶
  参考文献：
  名称：

  Nicotinamide derivatives useful as PDE4 inhibitors

  摘要：

  这项发明涉及一般式（I）的烟酰胺衍生物： 其中R1、R2和R3具有本文中定义的含义，并且涉及用于制备、用于制备的中间体、含有这种衍生物的组合物以及这种衍生物的用途的过程。

  公开号：

  US20050020626A1
• 作为产物：
  描述：

  2-氨基烟酸 在 氯化亚砜 作用下， 以 乙醇 、 水 为溶剂， 反应 22.0h， 生成 咪唑并[1,2-A]吡啶-8-甲酸甲酯
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1

  摘要：

  揭示了公式（I）中的CCR1受体拮抗剂，其中Ar1、Ar2、R1-R3、X和L在此处披露。还披露了公式（I）化合物的组成、制备方法和使用方法。

  公开号：

  WO2011056440A1

文献信息

• [EN] SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION<br/>[FR] COMPOSÉS BENZALDÉHYDE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION DE CEUX-CI DANS L'AUGMENTATION DE L'OXYGÉNATION DES TISSUS
  申请人：GLOBAL BLOOD THERAPEUTICS INC

  公开号：WO2013102142A1

  公开（公告）日：2013-07-04

  Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.

  提供了替代苯甲醛及其衍生物，其作为血红蛋白的变构调节剂，以及其制备的方法和中间体，包括这些调节剂的药物组合物，以及在治疗由血红蛋白介导的疾病和需要增加组织氧合的疾病中使用它们的方法。
• Novel compounds
  申请人：Smith Helen Mya Coral

  公开号：US20050020639A1

  公开（公告）日：2005-01-27

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , X, Y, Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  这项发明涉及一般式（I）的烟酰胺衍生物： 其中R 1 ，X，Y，Z和R 2 具有本文中定义的含义，并且涉及用于制备、用于制备的中间体、含有和使用这种衍生物的组合物的过程。
• Compounds
  申请人：Barber Gordon Christopher

  公开号：US20050020611A1

  公开（公告）日：2005-01-27

  This invention relates to nicotinamide derivatives of general formula (I): in which R 1 , Z and R 2 have the meanings defined herein, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of such derivatives.

  这项发明涉及一般式(I)的烟酰胺衍生物： 其中R1、Z和R2具有本文所定义的含义，并涉及用于制备、用于制备的中间体、含有和使用这种衍生物的组合物的过程。
• Imidazo(1,2-a)pyridines. I. Synthesis and Inotropic Activity of New 5-Imidazo(1,2-a)pyridinyl-2(1H)-pyridinone Derivatives.
  作者：Motosuke YAMANAKA、Kazutoshi MIYAKE、Shinji SUDA、Hideto OHHARA、Toshiaki OGAWA

  DOI：10.1248/cpb.39.1556

  日期：——

  A series of 1, 2-dihydro-5-imidazo[1, 2-α]pyridinyl-2(1H)-pyridonones was synthesized and evaluated for positive inotropic activity. 1, 2-Dihydro-5-imidazo[1, 2-α]pyridin-6-yl-6-methyl-2-oxo-3-pyridinecarbonitrile (11a) hydrochloride monohydrate (E-1020) was found to be a potent and selective inhibitor of phosphodiesterase III and a long-acting, potent, orally active positive inotropic agent. Additional imidazo[1, 2-α]pyridin-2-yl (3a), -3-yl (16), -7-yl (20) and -8-yl (24a) compounds were also prepared. Altering the pyridine substitution from the 2-position to the 6-position produced a 2-fold increse in the i.v. cardiotonic potency (ED50) from 52 to 23 μg/kg, while substitution at the 3-, 7- or 8-position reduced potency. In the 2-positional isomers, introduction of halogen groups enhanced the activity and 3-chloro-1, 2-dihydro-5-(6-fluoroimidazo[1, 2-α]pyridin-2-yl)-6-methyl-2(1H)-pyridinone (3u) was the most potent (i.v. ED50 11 μg/kg) in this series. E-1020 is presently under development for the treatment of congestive heart failure.

  合成了一系列1,2-二氢-5-咪唑[1,2-α]吡啶基-2(1H)-吡啶酮，并评估了它们的正性变力活性。1,2-二氢-5-咪唑[1,2-α]吡啶-6-基-6-甲基-2-氧-3-吡啶腈(11a)盐酸盐一水合物(E-1020)被发现是一种强效且选择性的磷酸二酯酶III抑制剂，以及一种长效、强效、口服活性正性变力剂。还制备了额外的咪唑[1,2-α]吡啶-2-基(3a)、-3-基(16)、-7-基(20)和-8-基(24a)化合物。将吡啶取代从2位改变到6位，静脉注射强心效力(ED50)从52增加到23 μg/kg，增加了2倍，而在3-、7-或8位取代则降低了效力。在2位异构体中，引入卤素基团增强了活性，3-氯-1,2-二氢-5-(6-氟咪唑[1,2-α]吡啶-2-基)-6-甲基-2(1H)吡啶酮(3u)是该系列中最强效的(静脉ED50 11 μg/kg)。E-1020目前正在开发用于治疗充血性心力衰竭。
• [EN] INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE<br/>[FR] THIADIAZOLAMINES INDAZOLYLE ET COMPOSÉS APPARENTÉS POUR L'INHIBITION DE PROTÉINE KINASE ASSOCIÉE À RHO ET LE TRAITEMENT DE MALADIES
  申请人：LYCERA CORP

  公开号：WO2016138335A1

  公开（公告）日：2016-09-01

  The invention provides indazolyl thiadiazolamines and related compounds, pharmaceutical compositions, methods of inhibiting Rho-associated protein kinase, and methods of treating inflammatory disorders, immune disorders, fibrotic disorders, and other medical disorders using such compounds. An exemplary indazolyl thiadiazolamine compound is an N-(5-[5-[(1H4ndazol-5-yl)amino]-1,3,4-thiadiazol-2-yl]pyridin-3-yl)acetamide compound.

  这项发明提供了吲唑基噻二唑胺及相关化合物、药物组合物、抑制Rho相关蛋白激酶的方法，以及利用这些化合物治疗炎症性疾病、免疫性疾病、纤维化疾病和其他医学疾病的方法。一种示例性的吲唑基噻二唑胺化合物是N-(5-[5-[(1H-吲唑-5-基)氨基]-1,3,4-噻二唑-2-基]吡啶-3-基)乙酰胺化合物。